Ultragenyx Pharmaceutical
RARE
161 hedge funds and large institutions have $3.39B invested in Ultragenyx Pharmaceutical in 2015 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 89 increasing their positions, 30 reducing their positions, and 22 closing their positions.
197% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 30
50% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 22
7% more funds holding
Funds holding: 151 → 161 (+10)
2% more capital invested
Capital invested by funds: $3.33B → $3.39B (+$66.4M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less call options, than puts
Call options by funds: $21.7M | Put options by funds: $35.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$83.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$48M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.4M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$40.6M |
| 5 |
Goldman Sachs
New York
|
+$39.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$124M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$56.8M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$22.2M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$21.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$21.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MACM
176
March Altus Capital Management
Greenwich,
Connecticut
| – | -$338K | -3,299 | Closed |
|
177
M&T Bank
Buffalo,
New York
| – | -$276K | -2,694 | Closed |
|
178
HSBC Holdings
London,
United Kingdom
| – | -$219K | -2,141 | Closed |
|
|
FANJ
179
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$141K | -1,380 | Closed |
|
|
DADC
180
D.A. Davidson & Co
Great Falls,
Montana
| – | -$7K | -70 | Closed |
|
181
Invesco
Atlanta,
Georgia
| – | -$5K | -53 | Closed |
|
|
TRCT
182
Tower Research Capital (TRC)
New York
| – | -$5K | -50 | Closed |
|
|
KCPG
183
Kavar Capital Partners Group
Leawood,
Kansas
| – | +$114 | +1 | +20% |
|
RARE Hedge Fund Activity: Q3 2015 in Review
161 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2015, worth a combined $3.39B — up 2% from $3.33B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new RARE positions and 22 closed out — a net gain of 11 holders — while 89 added to existing stakes and 30 trimmed.
The largest buyer was Wells Fargo, adding an estimated $83.2M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $124M.
- 161 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2015, up from 151 in Q2 2015.
- Funds reported $3.39B of Ultragenyx Pharmaceutical stock for Q3 2015, up 2% quarter-over-quarter.
- 33 funds opened new Ultragenyx Pharmaceutical positions in Q3 2015 and 22 closed out, a net change of +11 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2015 was Wells Fargo, an estimated $83.2M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2015 was Columbia Wanger Asset Management, an estimated $124M sold.
Based on aggregated 13F filings for Q3 2015.